These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Practicalities in running early-phase trials using the time-to-event continual reassessment method (TiTE-CRM) for interventions with long toxicity periods using two radiotherapy oncology trials as examples. van Werkhoven E; Hinsley S; Frangou E; Holmes J; de Haan R; Hawkins M; Brown S; Love SB BMC Med Res Methodol; 2020 Jun; 20(1):162. PubMed ID: 32571298 [TBL] [Abstract][Full Text] [Related]
27. Adaptive prior variance calibration in the Bayesian continual reassessment method. Zhang J; Braun TM; Taylor JM Stat Med; 2013 Jun; 32(13):2221-34. PubMed ID: 22987660 [TBL] [Abstract][Full Text] [Related]
28. Application of the continual reassessment method to a phase I dose-finding trial in Japanese patients: East meets West. Morita S Stat Med; 2011 Jul; 30(17):2090-7. PubMed ID: 21500239 [TBL] [Abstract][Full Text] [Related]
29. A nonparametric Bayesian method for dose finding in drug combinations cancer trials. Razaee ZS; Cook-Wiens G; Tighiouart M Stat Med; 2022 Mar; 41(6):1059-1080. PubMed ID: 35075652 [TBL] [Abstract][Full Text] [Related]
30. A hybrid Bayesian adaptive design for dose response trials. Chang M; Chow SC J Biopharm Stat; 2005; 15(4):677-91. PubMed ID: 16022172 [TBL] [Abstract][Full Text] [Related]
31. Accuracy, Safety, and Reliability of Novel Phase I Trial Designs. Zhou H; Yuan Y; Nie L Clin Cancer Res; 2018 Sep; 24(18):4357-4364. PubMed ID: 29661774 [TBL] [Abstract][Full Text] [Related]
32. Adaptive designs for dose-finding in non-cancer phase II trials: influence of early unexpected outcomes. Resche-Rigon M; Zohar S; Chevret S Clin Trials; 2008; 5(6):595-606. PubMed ID: 19029208 [TBL] [Abstract][Full Text] [Related]
33. The continual reassessment method: comparison of Bayesian stopping rules for dose-ranging studies. Zohar S; Chevret S Stat Med; 2001 Oct; 20(19):2827-43. PubMed ID: 11568943 [TBL] [Abstract][Full Text] [Related]
34. The continual reassessment method and its applications: a Bayesian methodology for phase I cancer clinical trials. Ishizuka N; Ohashi Y Stat Med; 2001 Sep 15-30; 20(17-18):2661-81. PubMed ID: 11523075 [TBL] [Abstract][Full Text] [Related]
39. Dose-escalation designs in oncology: ADEPT and the CRM. Shu J; O'Quigley J Stat Med; 2008 Nov; 27(26):5345-53; discussion 5354-5. PubMed ID: 18752259 [TBL] [Abstract][Full Text] [Related]
40. A nonparametric Bayesian continual reassessment method in single-agent dose-finding studies. Tang N; Wang S; Ye G BMC Med Res Methodol; 2018 Dec; 18(1):172. PubMed ID: 30563454 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]